Mary Washington Healthcare Introduces Accurate, Non-Invasive,
Painless Option to Aid in Liver Management
Fredericksburg, VA - (April 27, 2018) - Mary Washington Healthcare (MWHC)
is pleased to announce it now offers patients non-invasive, painless liver
assessments with FibroScan®, the first device to be FDA-cleared as
an aid to management of patients with liver disease.
An examination with FibroScan®, also called transient elastography,
is a non-invasive way to measure the stiffness of the patient’s
liver. FibroScan® works by emitting a small pulse of energy, which
may feel as a slight vibration on your skin. FibroScan calculates the
speed of this energy to give your healthcare provider an immediate measure
of the stiffness of your liver. This stiffness measure can be an important
part of understanding your overall liver health. FibroScan® examinations
are covered by most insurance plans.
“We are pleased to offer this important advance in liver management
to our patients. Its consistent results enable us to make the most informed
treatment decisions while providing the quick, painless experience patients
want,” said Dr. Peter Wong, MD, FACP, FACG, MWHC Endoscopy Chairman
and practicing gastroenterologist with Gastroenterology Associates of
Fredericksburg,
###
Mary Washington Healthcare
is a fully integrated, regional medical system that provides inpatient
and outpatient care through more than 40 facilities and services including
Mary Washington Hospital, a 451-bed regional medical center, and Stafford
Hospital, a 100-bed community hospital. Mary Washington Healthcare is
a not-for-profit health system with a longstanding commitment to provide
care regardless of ability to pay. For more information about our services and facilities, please visit www.mwhc.com.